Dongsheng Tu
机构: Professor of Biostatistics, Queen's University at Kingston, Canada
每年引用次数
引用次数
引用: 50,542
H-指数: 84
I10-指数 : 235
出版物: 544
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
Kim N. Chi , Lillian L. Siu , Hal Hirte , Sebastien J. Hotte
Clinical Cancer Research 14 ( 3) 833 -839
111
2008
Alternate Endpoints for Screening Phase II Studies
Neesha Dhani , Dongsheng Tu , Daniel J Sargent , Lesley Seymour
Clinical Cancer Research 15 ( 6) 1873 -1882
72
2009
Lessons Learned in the Assessment of Health-Related Quality of Life: Selected Examples From the National Cancer Institute of Canada Clinical Trials Group
Michael Brundage , David Osoba , Andrea Bezjak , Dongsheng Tu
Journal of Clinical Oncology 25 ( 32) 5078 -5081
35
2007
Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16
Michael Crump , Stefan Gluck , Dongsheng Tu , Doug Stewart
Journal of Clinical Oncology 26 ( 1) 37 -43
52
2008
Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
Paul E. Goss , James N. Ingle , Joseph L. Pater , Silvana Martino
Journal of Clinical Oncology 26 ( 12) 1948 -1955
158
2008
Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17
Hyman B. Muss , Dongsheng Tu , James N. Ingle , Silvana Martino
Journal of Clinical Oncology 26 ( 12) 1956 -1964
120
2008
Phase II stopping rules that employ response rates and early progression.
John R. Goffin , Dongsheng Tu
Journal of Clinical Oncology 26 ( 22) 3715 -3720
15
2008
Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group
Scott A. Laurie , Isabelle Gauthier , Andrew Arnold , Frances A. Shepherd
Journal of Clinical Oncology 26 ( 11) 1871 -1878
112
2008
NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting
Michael Brundage , Andrea Bezjak , Dongsheng Tu , Michael Palmer
Expert Review of Pharmacoeconomics & Outcomes Research 8 ( 3) 243 -253
2008
Adjustment of Treatment Effect for Covariates in Clinical Trials: Statistical and Regulatory Issues
Dongsheng Tu , Katherine Shalay , Joseph Pater
Drug Information Journal 34 ( 2) 511 -523
37
2000
On the Applications of Fisher’s Least Significant Difference (LSD) Procedure in Three-Arm Clinical Trials with Survival Endpoints
Shifting Liu , Dongsheng Tu
Drug Information Journal 42 ( 1) 81 -91
4
2008
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock , Derek J. Jonker , Federica Di Nicolantonio , Andrea Sartore-Bianchi
JAMA 304 ( 16) 1812 -1820
839
2010
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).
Christopher M. Booth , Kerry S. Courneya , Janette L. Vardy , Derek J. Jonker
Journal of Clinical Oncology 31
1
2013
Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.
Wilson Kwong , Graeme A Fraser , Ronald Barr , Dongsheng Tu
Journal of Clinical Oncology 31
2013
A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials
John R Goffin , Greg R Pond , Dongsheng Tu
BMC Medical Research Methodology 11 ( 1) 95 -95
3
2011
A Comparative Study of Some Statistical Procedures in Establishing Therapeutic Equivalence of Nonsystemic Drugs with Binary Endpoints
Dongsheng Tu
Drug Information Journal 31 ( 4) 1291 -1300
13
1997
Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
Huan Jin , Dongsheng Tu , Naiqing Zhao , Lois E. Shepherd
Journal of Clinical Oncology 30 ( 7) 718 -721
111
2012
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer.
Rachel Goodwin , Derek Jonker , Eric Chen , Hagen Kennecke
Investigational New Drugs 38 ( 4) 1077 -1084
13
2020
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study
Sarah Lapointe , Warren Mason , Mary MacNeil , Craig Harlos
Investigational New Drugs 38 ( 4) 1137 -1144
7
2020
A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.
Kelvin K. Chan , Dongsheng Tu , Christopher J. O'Callaghan , Heather-Jane Au
Journal of Clinical Oncology 32 547 -547
2014
Lois Shepherd Lesley Seymour Kathleen I. Pritchard C Karapetis John Zalcberg Jeremy Shapiro Timothy Price Christopher J O'Callaghan Michael Brundage Wendy R. Parulekar Ian Gilron John Goffin Lillian Siu Ronald R. Holden Nancy E Davidson Penelope Bradbury Stephen KL Chia Zee Chung-Ying Benny Ming Tsao Sharlene Gill